Sweden’s Sobi has kicked off a rolling biologics license application in the US for SEL-212, vying to become a new option for patients with refractory chronic gout that doesn’t respond to current ...

Expands Sobi’s pipeline with a highly differentiated new Phase 3 asset in Gout Acquisition expected to be highly accretive to Sobi’s mid- to long-term growth and margin trajectory Sobi® (STO:SOBI) has ...

Sobi has entered into an agreement to acquire Arthrosi Therapeutics, a private late-stage biotechnology company specialising in the development of a treatment for gout. The acquisition will strengthen ...

Sobi, which currently has a drug under FDA review as a later line of therapy for gout, is paying $950 million to acquire Arthrosi Therapeutics, a startup with a gout drug candidate in Phase 3 ...

Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Sobi's acquisition of Arthrosi Therapeutics for $1.5 billion includes pozdeutinurad, a promising gout treatment asset. Pozdeutinurad, a URAT1 inhibitor, shows efficacy in reducing serum uric acid and ...

For $950 million upfront, Sobi will gain ownership to pozdeutinurad, an oral URAT1 inhibitor that performed well in Phase II studies. Sobi is taking over California-based Arthrosi Therapeutics in a ...

Expands Sobi's pipeline with a highly differentiated new Phase 3 asset in Gout Acquisition expected to be highly accretive to Sobi's mid- to long-term growth and margin trajectory STOCKHOLM, Dec. 13, ...

Sobi plans to fund the upfront payment primarily through existing credit facilities and a new credit facility provided by Handelsbanken and Danske Bank. With $779 million in levered free cash flow ...

STOCKHOLM, Oct. 21, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), a global biopharmaceutical company today announced that Helena Saxon a member of the Sobi board of Directors, has resigned her position ...

Swedish Orphan Biovitrum AB (OTCPK:BIOVF) has announced a significant upgrade to its full-year 2025 financial outlook, driven by exceptional Q3 performance, disciplined cost control, and strategic ...